JP2023500483A5 - - Google Patents
Info
- Publication number
- JP2023500483A5 JP2023500483A5 JP2022525101A JP2022525101A JP2023500483A5 JP 2023500483 A5 JP2023500483 A5 JP 2023500483A5 JP 2022525101 A JP2022525101 A JP 2022525101A JP 2022525101 A JP2022525101 A JP 2022525101A JP 2023500483 A5 JP2023500483 A5 JP 2023500483A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135814A JP7688769B2 (ja) | 2019-10-30 | 2024-08-15 | Ｃｄ７３阻害剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928138P | 2019-10-30 | 2019-10-30 | |
| US62/928,138 | 2019-10-30 | ||
| US202062987806P | 2020-03-10 | 2020-03-10 | |
| US62/987,806 | 2020-03-10 | ||
| US202063088646P | 2020-10-07 | 2020-10-07 | |
| US63/088,646 | 2020-10-07 | ||
| PCT/US2020/057996 WO2021087136A1 (en) | 2019-10-30 | 2020-10-29 | Cd73 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135814A Division JP7688769B2 (ja) | 2019-10-30 | 2024-08-15 | Ｃｄ７３阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023500483A JP2023500483A (ja) | 2023-01-06 |
| JP2023500483A5 true JP2023500483A5 (https=) | 2023-10-13 |
| JPWO2021087136A5 JPWO2021087136A5 (https=) | 2023-10-13 |
| JP7544815B2 JP7544815B2 (ja) | 2024-09-03 |
Family
ID=75686256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525101A Active JP7544815B2 (ja) | 2019-10-30 | 2020-10-29 | Ｃｄ７３阻害剤 |
| JP2024135814A Active JP7688769B2 (ja) | 2019-10-30 | 2024-08-15 | Ｃｄ７３阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135814A Active JP7688769B2 (ja) | 2019-10-30 | 2024-08-15 | Ｃｄ７３阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US11530236B2 (https=) |
| EP (2) | EP4051688B1 (https=) |
| JP (2) | JP7544815B2 (https=) |
| KR (2) | KR102653726B1 (https=) |
| CN (2) | CN116854758A (https=) |
| AU (1) | AU2020375914B2 (https=) |
| CA (1) | CA3159248C (https=) |
| DK (1) | DK4051688T3 (https=) |
| ES (1) | ES3034168T3 (https=) |
| FI (1) | FI4051688T3 (https=) |
| HU (1) | HUE072504T2 (https=) |
| IL (2) | IL308293B2 (https=) |
| MX (1) | MX2022005256A (https=) |
| PL (1) | PL4051688T3 (https=) |
| PT (1) | PT4051688T (https=) |
| SI (1) | SI4051688T1 (https=) |
| TW (1) | TWI830962B (https=) |
| WO (1) | WO2021087136A1 (https=) |
| ZA (1) | ZA202204941B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2024059609A1 (en) * | 2022-09-14 | 2024-03-21 | Oric Pharmaceuticals, Inc. | Pharmaceutical forms of a cd73 inhibitor |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024076873A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2025111247A1 (en) * | 2023-11-20 | 2025-05-30 | Oric Pharmaceuticals, Inc. | Treatment of refractory multiple myeloma |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023991A (en) | 1911-07-29 | 1912-04-23 | Firm B Byers | Anti-rail-creeper and splice-bar. |
| EP0477454A1 (en) | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| WO2015164573A1 (en) | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| EA036379B1 (ru) * | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| HUE063388T2 (hu) * | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| TWI767937B (zh) | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| CN110049767B (zh) * | 2016-10-03 | 2023-04-04 | 艾库斯生物科学有限公司 | 腺苷5′-核苷酸酶的抑制剂 |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| WO2019129059A1 (zh) | 2017-12-29 | 2019-07-04 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| EP3843714B1 (en) | 2018-08-27 | 2025-11-12 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| KR20220024629A (ko) | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
-
2020
- 2020-10-29 HU HUE20883288A patent/HUE072504T2/hu unknown
- 2020-10-29 EP EP20883288.1A patent/EP4051688B1/en active Active
- 2020-10-29 US US17/083,871 patent/US11530236B2/en active Active
- 2020-10-29 IL IL308293A patent/IL308293B2/en unknown
- 2020-10-29 TW TW109137697A patent/TWI830962B/zh active
- 2020-10-29 MX MX2022005256A patent/MX2022005256A/es unknown
- 2020-10-29 PT PT208832881T patent/PT4051688T/pt unknown
- 2020-10-29 ES ES20883288T patent/ES3034168T3/es active Active
- 2020-10-29 EP EP25170469.8A patent/EP4596048A3/en active Pending
- 2020-10-29 KR KR1020227018155A patent/KR102653726B1/ko active Active
- 2020-10-29 US US17/771,711 patent/US12577272B2/en active Active
- 2020-10-29 AU AU2020375914A patent/AU2020375914B2/en active Active
- 2020-10-29 KR KR1020247010203A patent/KR102727229B1/ko active Active
- 2020-10-29 PL PL20883288.1T patent/PL4051688T3/pl unknown
- 2020-10-29 DK DK20883288.1T patent/DK4051688T3/da active
- 2020-10-29 WO PCT/US2020/057996 patent/WO2021087136A1/en not_active Ceased
- 2020-10-29 CN CN202310805820.7A patent/CN116854758A/zh active Pending
- 2020-10-29 SI SI202030633T patent/SI4051688T1/sl unknown
- 2020-10-29 IL IL292570A patent/IL292570B2/en unknown
- 2020-10-29 FI FIEP20883288.1T patent/FI4051688T3/fi active
- 2020-10-29 JP JP2022525101A patent/JP7544815B2/ja active Active
- 2020-10-29 CN CN202080091505.7A patent/CN114929721B/zh active Active
- 2020-10-29 CA CA3159248A patent/CA3159248C/en active Active
- 2020-12-08 US US17/114,993 patent/US11028120B2/en active Active
-
2021
- 2021-03-17 US US17/204,272 patent/US11130778B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04941A patent/ZA202204941B/en unknown
- 2022-10-31 US US18/051,125 patent/US12018043B2/en active Active
-
2024
- 2024-05-10 US US18/660,815 patent/US12454544B2/en active Active
- 2024-08-15 JP JP2024135814A patent/JP7688769B2/ja active Active
-
2025
- 2025-10-22 US US19/365,693 patent/US20260042794A1/en active Pending